The World's Leading Center for APL Treatment
Ruijin Hospital's Hematology Department, affiliated with Shanghai Jiao Tong University School of Medicine, is home to one of the most celebrated achievements in modern oncology: the development of the "Shanghai Protocol" for acute promyelocytic leukemia (APL) — a combination of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) that has transformed APL from one of the most fatal leukemias into one of the most curable cancers in the world. This breakthrough was pioneered by Academician Chen Zhu (陈竹) and his colleagues, including Academician Chen Saijuan, whose combined work has saved tens of thousands of lives globally. Today, Ruijin Hospital remains the world reference center for APL treatment and precision hematology.
What the Program Offers
Ruijin Hospital's APL and Precision Hematology Program offers international patients access to:
- Acute promyelocytic leukemia (APL) treatment using the original Shanghai Protocol (ATO + ATRA)
- Relapsed and refractory APL — including patients who have failed standard therapy elsewhere
- Molecular monitoring of APL remission using PML-RARα PCR — the gold standard for treatment response assessment
- Acute myeloid leukemia (AML) — molecular subtyping and precision targeted therapy
- Precision hematology: next-generation sequencing (NGS) for comprehensive leukemia mutation profiling
- CAR-T cell therapy evaluation and access
- Bone marrow transplantation (allogeneic and autologous) for eligible patients
- Clinical trials of novel targeted agents and immunotherapies
- Second opinions on leukemia diagnosis and treatment plans from one of the world's top hematology teams
Why International Patients Come to Ruijin for APL
For patients diagnosed with APL anywhere in the world, Ruijin Hospital represents the ultimate reference center — the institution where the curative protocol was developed and where the world's largest APL patient cohort has been treated. For patients with relapsed APL, or those whose disease has not achieved molecular remission, the expertise available at Ruijin Hospital is unmatched globally. The team led by Academician Chen Saijuan continues to lead the world in APL research and clinical innovation, ensuring patients benefit from the very latest advances in precision hematology. For patients with other leukemias seeking a second opinion or access to novel therapies, Ruijin's comprehensive molecular diagnostics and clinical trial portfolio make it one of the most compelling destinations for hematological cancer care in Asia.
How CMCS Arranges Your Consultation
CMCS manages every aspect of your medical visit so you can focus on your health and treatment. Here's how we help:
- Initial Consultation: Contact CMCS and share your bone marrow biopsy reports, molecular testing results, cytogenetics, and treatment history.
- Case Review: Our team reviews your case and identifies the most appropriate specialist within Ruijin's Hematology Department.
- Appointment Booking: We coordinate directly with Ruijin Hospital to secure your consultation, including urgent cases when needed.
- Pre-Visit Preparation: We advise on which pathology materials, molecular test results, and treatment records to bring or send in advance.
- On-the-Day Support: A CMCS coordinator accompanies you through registration, consultation, and any same-day bone marrow procedures or blood tests.
- Treatment Coordination: If treatment at Ruijin is recommended, CMCS helps coordinate hospital admission, chemotherapy scheduling, and ongoing care logistics.
What to Prepare Before Your Visit
To ensure the most productive consultation, please prepare:
- Complete bone marrow biopsy report: morphology, immunophenotyping (flow cytometry), cytogenetics (karyotype, FISH), molecular testing (PML-RARα for APL; NGS panel for other leukemias)
- Recent blood counts: CBC with differential, coagulation profile (DIC screen — essential for APL)
- Records of all prior treatment: chemotherapy regimens, ATO/ATRA therapy details, response assessments
- Molecular remission monitoring results (PML-RARα PCR results if available)
- Pathology slides (original bone marrow trephine biopsy slides if possible)
- A full list of current medications
- Your passport and travel/health insurance documents
What to Expect on the Day
Ruijin Hospital's Hematology Department is equipped with state-of-the-art molecular diagnostics, flow cytometry, cytogenetics, and a dedicated leukemia research laboratory. Your consultation will involve a thorough review of your molecular and pathological data, followed by a detailed discussion of your diagnosis, remission status, and treatment options. CMCS will ensure all communication is clear and that you leave with a complete understanding of your disease and the recommended plan. For patients requiring bone marrow transplant evaluation or access to novel clinical trials, we can coordinate all necessary steps within Ruijin Hospital seamlessly.
Contact CMCS to Get Started
Ready to access Ruijin Hospital's world-leading APL and precision hematology program? Contact our team today:
CMCS is your trusted medical concierge partner in Shanghai — making world-class Chinese healthcare accessible to international patients.
0件のコメント